Patents by Inventor Byron Hua Kwan

Byron Hua Kwan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SYNERGISTIC TUMOR TREATMENT WITH IL-2 AND INTEGRIN-BINDING-FC FUSION PROTEIN
    Publication number: 20220193197
    Abstract: The present invention provides a method of treating cancer with a combination of IL-2 and an integrin-binding-Fc fusion protein. The methods of the invention can be applied to a broad range of cancer types.
    Type: Application
    Filed: August 19, 2021
    Publication date: June 23, 2022
    Inventors: Karl Dane WITTRUP, Jennifer R. COCHRAN, Byron Hua KWAN
  • Synergistic tumor treatment with an extended pharmacokinetic IL-2 and integrin-binding-Fc fusion protein
    Patent number: 11096989
    Abstract: The present invention provides a method of treating cancer with a combination of IL-2 and an integrin-binding-Fc fusion protein. The methods of the invention can be applied to a broad range of cancer types.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: August 24, 2021
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Karl Dane Wittrup, Jennifer R. Cochran, Byron Hua Kwan
  • ANTI-PD-L1 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES
    Publication number: 20210101982
    Abstract: Provided are novel anti-PD-L1 antibodies and antibody-drug conjugates and methods of using such anti-PD-L1 antibodies and antibody-drug conjugates to treat cancer.
    Type: Application
    Filed: October 2, 2020
    Publication date: April 8, 2021
    Inventors: Byron Hua Kwan, Heather Van Epps, Andrew Waight
  • Methods of treating cancer cells expressing tumor-associated integrins
    Patent number: 10888603
    Abstract: The present invention provides a method of treating cancer with a combination of IL-2 (e.g., extended-PK IL-2), an integrin-binding-Fc fusion protein, and a cancer vaccine. The methods of the invention can be used to treat a broad range of cancer types.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: January 12, 2021
    Assignees: The Board of Trustees of the Leland Stanford Junior University, Massachusetts Institute of Technology
    Inventors: Karl Dane Wittrup, Darrell J. Irvine, Cary Francis Opel, Kelly Dare Moynihan, Jennifer R. Cochran, Byron Hua Kwan
  • SYNERGISTIC TUMOR TREATMENT WITH IL-2 AND INTEGRIN-BINDING-FC FUSION PROTEIN
    Publication number: 20190343925
    Abstract: The present invention provides a method of treating cancer with a combination of IL-2 and an integrin-binding-Fc fusion protein. The methods of the invention can be applied to a broad range of cancer types.
    Type: Application
    Filed: December 21, 2018
    Publication date: November 14, 2019
    Inventors: Karl Dane WITTRUP, Jennifer R. COCHRAN, Byron Hua KWAN
  • SYNERGISTIC TUMOR TREATMENT WITH IL-2, AN INTEGRIN-BINDING-FC FUSION PROTEIN, AND A CANCER VACCINE
    Publication number: 20190054145
    Abstract: The present invention provides a method of treating cancer with a combination of IL-2 (e.g., extended-PK IL-2), an integrin-binding-Fc fusion protein, and a cancer vaccine. The methods of the invention can be used to treat a broad range of cancer types.
    Type: Application
    Filed: February 10, 2017
    Publication date: February 21, 2019
    Inventors: Karl Dane WITTRUP, Darrell J. IRVINE, Cary Francis OPEL, Kelly Dare MOYNIHAN, Jennifer R. COCHRAN, Byron Hua KWAN
  • Synergistic tumor treatment with antibodies targeting PD-1, PD-L1 or CTLA4 and integrin-binding-Fc-fusion protein
    Patent number: 10166273
    Abstract: The present invention provides a method of treating cancer with a combination of IL-2 and an integrin-binding-Fc fusion protein. The methods of the invention can be applied to a broad range of cancer types.
    Type: Grant
    Filed: August 12, 2015
    Date of Patent: January 1, 2019
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Karl Dane Wittrup, Jennifer R. Cochran, Byron Hua Kwan
  • Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
    Patent number: 9844582
    Abstract: The present invention relates to methods of treating cancer with a combination of extended-PK IL-2 and one or more therapeutic agents, such as a therapeutic antibody. The methods of the invention are applicable across any type of cancer.
    Type: Grant
    Filed: May 21, 2013
    Date of Patent: December 19, 2017
    Assignee: Massachusetts Institute of Technology
    Inventors: Karl Dane Wittrup, Byron Hua Kwan, Shuning Gai
  • SYNERGISTIC TUMOR TREATMENT WITH IL-2 AND INTEGRIN-BINDING-FC-FUSION PROTEIN
    Publication number: 20170216402
    Abstract: The present invention provides a method of treating cancer with a combination of IL-2 and an integrin-binding-Fc fusion protein. The methods of the invention can be applied to a broad range of cancer types.
    Type: Application
    Filed: August 12, 2015
    Publication date: August 3, 2017
    Inventors: Karl Dane WITTRUP, Jennifer R. COCHRAN, Byron Hua KWAN
  • SYNERGISTIC TUMOR TREATMENT WITH EXTENDED-PK IL-2 AND THERAPEUTIC AGENTS
    Publication number: 20150132254
    Abstract: The present invention relates to methods of treating cancer with a combination of extended-PK IL-2 and one or more therapeutic agents, such as a therapeutic antibody. The methods of the invention are applicable across any type of cancer.
    Type: Application
    Filed: May 21, 2013
    Publication date: May 14, 2015
    Inventors: Karl Dane Wittrup, Byron Hua Kwan, Shuning Gai